regulatory
confidence high
sentiment positive
materiality 0.60
Perspective Therapeutics wins FDA Fast Track for PSV359 in FAP-positive solitary fibrous tumors
Perspective Therapeutics, Inc.
- FDA granted Fast Track Designation for [212Pb]PSV359 in adults with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors (SFTs).
- PSV359 is an investigational FAP-targeted alpha-particle therapy using the alpha-emitting isotope 212Pb, now in an ongoing Phase 1/2a study in advanced FAP-positive solid tumors.
- Fast Track may bring more frequent FDA interactions and eligibility for rolling review, Accelerated Approval, or Priority Review if criteria are met.
- CMO Markus Puhlmann noted no approved therapies specifically target FAP-alpha; imaging of FAP expression allows patient selection for targeted alpha therapy.
- CEO Thijs Spoor called the designation an important step for the broader PSV359 program; SFT patients with unresectable/metastatic disease have limited options.